Psychedelic Drugs

Clinical trials show psilocybin provides rapid relief for depression, but the underlying biology remains unclear. New research demonstrates how varying doses of the drug bind to serotonin receptors to enhance cellular flexibility.

New research suggests that psilocybin shifts the brain from a relaxed state into a highly engaged pattern of rapid electrical activity. This measurable shift in brain waves provides evidence linking biological changes directly to subjective psychedelic experiences.

Published in Scientific Reports, new research provides evidence that minor compounds in psychedelic mushrooms work alongside psilocybin to interact with brain receptors. This chemical teamwork explains why whole mushroom extracts often affect people differently than isolated, lab-made psilocybin.

Archival records reveal that the 1971 global ban on psychedelics was fueled by Cold War politics and media sensationalism, not medical science. This historical analysis suggests international drug laws should be updated to reflect actual scientific evidence.

A recent study in Translational Psychiatry shows that one dose of DMT reversed loss of pleasure and cognitive deficits in stressed mice. The psychedelic promoted new brain cell growth, highlighting its potential as a rapid-acting antidepressant.

A new study in Communications Biology provides evidence that a psychedelic drug induces a hybrid sleep-wake state in active mice. This unusual brain activity suggests a potential mechanism for how psychedelics might help remodel neural connections.

A new mouse study published in the Journal of Psychopharmacology provides evidence that psilocybin selectively enhances the brain's ability to rewire itself. The research suggests that optimizing specific doses could help tailor treatments for different psychiatric symptoms.

New research reveals how ayahuasca alters brain waves to induce vivid, spontaneous thoughts. A simple brain recording before consumption can even predict how intensely a person will experience the brew's physical and emotional effects.

Researchers have identified a self-guided therapeutic process induced by magnesium-ibogaine. Published in npj Mental Health Research, the study sheds light on how veterans with brain injuries revisit traumatic memories to achieve psychological and cognitive healing.

Scientists have found evidence that LSD inhibits status epilepticus and mortality in mice. The preliminary research suggests the drug works by desynchronizing brain activity.

Chronic microdosing of psilocybin could fight obesity and diabetes without the "trip." Researchers discovered that non-hallucinogenic doses reduced weight gain and restored insulin sensitivity in mice by targeting specific receptors in the liver.

A study in European Neuropsychopharmacology finds that ayahuasca helps rats learn that a previously dangerous environment is safe. This effect appears to rely on BDNF signaling within the infralimbic cortex, suggesting a potential biological pathway for treating trauma.

A new systematic review suggests that recreational ecstasy users suffer from verbal memory impairments that do not improve even after months or years of quitting the drug.

Psilocybin’s effects are not uniform across different physiological conditions. A study of female mice reveals that exercise and diet drastically alter how the drug influences social interactions and inflammatory signaling.

Researchers found that a single dose of psilocybin alters the electrical properties of brain cells for months. This functional plasticity, rather than structural growth, may explain why psychedelic therapy offers enduring relief from depression.